Infection Control Overview
The Infection Control market is expected to grow at a CAGR of 13.3% from 2020 to 2027 to reach at USD 58.2 billion by 2027. Infectious diseases caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi can be spread, directly or indirectly, either from one person to another, from infected or non-sterilised surgical or medical devices used to treat a person, or from being in the infected environment of any healthcare facility.
Factors such as growing incidences of nosocomial infections, rising number of surgical procedures, increasing incidence of chronic diseases associated with growing geriatric population, and growing medical device reprocessing industry are expected to propel the growth of the global infection control market.
The severe impact of COVID-19, has realised unprecedented global demand for advanced healthcare facilities, services, and infrastructure to combat the infection. This has undeniably increased pressure on manufacturers to ensure their products penetrate an increasingly more competitive market.
With no upfront costs, Taruna Medical can help you drive sustained growth, ensuring costs are directly related to revenue. The Taruna Model offers an alternative and scalable route to market, reducing the fixed costs of manufacturers. If you operate within the area of infection prevention and are looking for a way to increase your reach without increasing your fixed costs, then please get in contact with us.